Guidelines issued by DoP for bulk drug parks

A brief guidelines for bulk drug parks and detailed guidelines will be released soon by
The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilisers, the Government of India. DoP has also announced the details of a financial assistance programme which includes grant-in-aid to three bulk drug parks with a total incentive of Rs 3000 crores for the construction of common infrastructure facilities.
Implementation of the proposed scheme will be done through a one time grant in aid and will be released in various phases for the creation of infrastructure in bulk drug to a State Implementing Agency.

The particular programme has a proposal to provide grant-in-aid to three bulk drug parks with a maximum limit of Rs 1000 crores per bulk drug park or 70 per cent of the project cost of common infrastructure facilities, as per the issued notification by Navdeep Rinwa, Joint Secretary, Department of Pharmaceuticals, .

The same notification also states that that in case of hilly regions and the North East Region, the grant-in-aid would be Rs 1000 crore per bulk drug park or 90 per cent of the project cost of common infrastructure facilities, whichever is less.

The proposed scheme would be helpful for infrastructure facilities like solvent recovery, distillation plant, central effluent treatment plant, common logistics facilities, advanced common testing centre, regulatory awareness facility centre, emergency response centre etc.

“We welcome the issued brief guidelines on bulk drug parks. The Himachal Pradesh Government is very keen on setting up the bulk drug park in the State with the help of the announced scheme by the Central Government. The State government is planning to acquire approximately 1350 acres of land, it has already identified 1000 bigha land and will be exploring the possibilities to acquire more land.” Dr Rajesh Gupta, a member of the Bulk Drug Park Committee, Himachal Pradesh and President, Himachal Drug Manufacturers Association (HDMA) told.

“We are reviewing the guidelines and will be discussing with the state industrial bodies.” said Ritu Sahay, Director-Drugs Controller, Jharkhand.

The proposal for application will be open from 2020-2021 to 2024-2025.

  • Related Posts

    • Pharma
    • April 19, 2024
    • 33 views
    US FDA Mandates Label Updates On CAR-T Cancer Therapies

    Washington: The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called “boxed warning” to highlight the serious risk of T-cell blood…

    • Pharma
    • April 19, 2024
    • 24 views
    Karnataka Fails To Take Action Against 1,700 Fake Doctors

    Bengaluru: A startling revelation has come to light nearly 17,00 fake doctors have been identified in the AYUSH department in Karnataka. Shockingly, despite these discoveries, no significant action has been taken…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    US FDA Mandates Label Updates On CAR-T Cancer Therapies

    US FDA Mandates Label Updates On CAR-T Cancer Therapies

    Karnataka Fails To Take Action Against 1,700 Fake Doctors

    Karnataka Fails To Take Action Against 1,700 Fake Doctors

    Chhattisgarh Pharmacy Council Issued Certificates For Hundreds Of Fake Pharmacists Without Verification

    Chhattisgarh Pharmacy Council Issued Certificates For Hundreds Of Fake Pharmacists Without Verification

    Gujarat FDCA Approved 133 New Drug Manufacturing Units In FY24

    Gujarat FDCA Approved 133 New Drug Manufacturing Units In FY24

    DCGI Informs SLAs Antibiotic Combo Meropenem 1 Mg & EDTA For Injection Has No Approval

    DCGI Informs SLAs Antibiotic Combo Meropenem 1 Mg & EDTA For Injection Has No Approval

    DCA Raids Two Illegal Pharmacies; Seizes Stocks Of Over 60 Types Of Drugs

    DCA Raids Two Illegal Pharmacies; Seizes Stocks Of Over 60 Types Of Drugs